|Bid||85.10 x 1400|
|Ask||84.85 x 800|
|Day's Range||84.20 - 87.67|
|52 Week Range||61.13 - 90.64|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||35.16|
|Forward Dividend & Yield||0.72 (0.85%)|
|Ex-Dividend Date||Jun 29, 2020|
|1y Target Est||N/A|
Shares in Agilent Technologies (A) rose 5% on Friday after the company reported revenue of $1.24B which beat Street estimates by $40M and came in flat on a year-over-year (y/y) basis.Q2 Non-GAAP EPS of $0.71 beat consensus by $0.10, although GAAP EPS of $0.32 misses by $0.17. The stock is now down 0.4% since the beginning of the year.Operating profit rose 2.2% y/y to $277M, while core revenue declined 1.7% y/y, reflecting the impact of Covid-19 business disruption (particularly within academic & government and chemical & energy end-markets).“Our business was tracking well into late March when we experienced significant disruption in the U.S. and Europe as customers closed or restricted access to their facilities to slow the spread of COVID-19,” said Mike McMullen, Agilent president and CEO.“I believe we are well-positioned to face the challenges brought on by COVID-19 given our focus on growth, a resilient business model, a strong balance sheet, and most importantly, our outstanding team” he added.Following earnings, Needham’s Stephen Unger reiterated his Hold rating without a price target. “Considering the COVID-19 environment, A’s FY2Q20 results were solid with adj. EPS growing 0.6% y/y to $0.71 – $0.04 below our model” he wrote.As a result, the analyst lowered his FY20 adj. EPS estimate from $3.42 to $3.02 (3% decline from FY19) on revenues of $5.122B (1.8% core revenue decline), a $388M reduction from his previous forecast.“Given increased downside potential associated with business disruption from the COVID-19 pandemic, we consider the lower half of the [stock’s current] trading range to approximate fair value ($79.00-89.00)” Unger told investors on May 22.Indeed, the majority of analysts covering A rate the stock a hold, with 7 recent hold ratings vs 4 buy ratings. The $89 average analyst price target indicates upside potential of 5%. (See Agilent stock analysis on TipRanks)Related News: Gilead and Galapagos Score Positive Topline Results For Ulcerative Colitis Trial Moderna Spikes 21% Amid “Positive” Early-Stage Covid-19 Vaccine Data AstraZeneca-Merck Lynparza Prostate Cancer Treatment Gets FDA Approval More recent articles from Smarter Analyst: * Gates Foundation Buys Up Amazon, Apple, Twitter Stock; Trims Berkshire Hathaway Stake * Earnings: RBC Forecasts Choppy Results For Dell This Thursday * Salesforce Earnings Preview: Five-Star Analyst Bullish Into Print * Weight Watchers Fires Thousands Over Zoom
The U.S. death toll from the coronavirus that causes COVID-19 edged closer to 100,000 on Friday, as the news emerged that the Centers for Disease Control and Prevention has been combining the results of two different types of tests for the illness in a move that has been sharply criticized by health experts.
Agilent's (A) second-quarter fiscal 2020 results reflect negative impact of coronavirus outbreak despite robust performance of the Diagnostics and Genomics Group.
Thank you, Jodi, and welcome everyone to Agilent's conference call for the second quarter of fiscal year 2020. On the webcast today are Mike McMullen, Agilent's President and CEO; and Bob McMahon, Agilent's Senior Vice President and CFO. Joining for the Q&A after prepared remarks will be Jacob Thaysen, President of Agilent's Life Science and Applied Markets Group; and Sam Raha, President of Agilent's Diagnostics and Genomics Group, along with Padraig McDonnell, President of the Agilent CrossLab Group.
Agilent (A) delivered earnings and revenue surprises of 22.41% and 5.23%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?
Agilent Technologies Inc. shares rose 3% in the extended session Thursday, after the company topped earnings and revenue expectations. Agilent reported second-quarter net income of $101 million, which amounts to 32 cents a share, compared with $182 million, or 57 cents a share, in the year-ago period. Adjusted for asset impairments, intangible amortization, among other items, earnings were 71 cents a share. Revenue was flat at $1.24 billion. Analysts polled by FactSet expected adjusted earnings of 61 cents a share on revenue of $1.21 billion. In a statement, Agilent Chief Executive Mike McMullen said that the company is well-positioned to "face the challenges" of the COVID-19 pandemic and the company was poised to focus on "growth, a resilient business model, and strong balance sheet, and most importantly, our outstanding team." Agilent stock has fallen 5.1% this year, as the S&P 500 index dropped 8%.
Agilent's (A) fiscal second-quarter results are likely to reflect the global coronavirus-driven economic crisis.
Health-care stocks that were popular in ESG funds tended to score better on ESG issues than other stocks in the sector in conventional funds, according to a study.
The online retailer and cloud giant is pouring millions into a developing a way to test its front-line workers. That has one analyst dreaming of Amazon as a force in testing.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Agilent Technologies, Inc. New York, May 15, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The U.S. death toll from the coronavirus that causes COVID-19 rose above 71,000 on Wednesday, as President Donald Trump appeared to back off his announcement that he would phase out the government task force created to manage the pandemic
NOTE: On May 05, 2020, the press release was corrected as follows: In the debt list, for Agilent Technologies, Inc., under Outlook action was changed to Maintained, Stable. Revised release follows. Concurrently, Moody's affirmed the Baa2 senior unsecured rating.
When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...
In his second 'Executive Decision' segment of Mad Money Thursday night, Jim Cramer checked in with Mike McMullen, CEO of Agilent Technologies , the life sciences company helping in the fight to beat Covid-19. McMullen said Agilent is active in virus research, virus testing and vaccine development. In the area of testing, he said Agilent provides key ingredients for the testing process and has technology to help provide test results faster.
Agilent (A) withdraws second-quarter and fiscal 2020 guidance owing to uncertainty surrounding the impact of coronavirus outbreak on the upcoming results.
The furloughs at headquarters come 10 days after Belk temporarily shut down its stores due to the novel coronavirus outbreak.